ASCO 2023 Annual Meeting

Comparative Efficacy of Intrathecally Administered Therapies for HER2+ Leptomeningeal Metastases
Comparative Efficacy of Intrathecally Administered Therapies for HER2+ Leptomeningeal Metastases
Dustin SamplesConferences | June 9, 2023
Does the route of administration for HER2 targeted therapy affect overall and progression-free survival?
Biological Changes Identified Between Primary Tumors and Brain Metastases
Biological Changes Identified Between Primary Tumors and Brain Metastases
Dustin SamplesConferences | June 9, 2023
Certain intrinsic molecular subtypes changed after metastasis compared to the primary tumor subtype.
Treatment Outcomes for HER2+ Breast Cancer With Brain Metastasis
Treatment Outcomes for HER2+ Breast Cancer With Brain Metastasis
Dustin SamplesConferences | June 9, 2023
Overall survival was the least favorable when brain metastasis was diagnosed during or after second-line treatment.
Prognostic Model for Risk-Stratified Overall Survival in HER2+ Breast Cancer With Brain Metastasis
Prognostic Model for Risk-Stratified Overall Survival in HER2+ Breast Cancer With Brain Metastasis
Dustin SamplesConferences | June 9, 2023
According to a novel prognostic model, patients classified as low-risk had better overall survival.
Advertisement
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • Connect

    eNewsletters

    Contact Us

    Contribute

    Calendar of Events

    Our Network

    Blood Cancers Today

    GU Oncology Now

    DocWire News

    MashupMD

    Urban Health Today

    About Us

    About Us

    Editorial Policy

    Authors

    Advertising

    © 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |